KCM
COGT icon

Kennedy Capital Management’s Cogent Biosciences COGT Stock Holding History

Kennedy Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7M Sell
353,790
-6,700
-2% -$234K 0.24% 146
2026
Q1 		$13.9M Buy
360,490
+8,103
+2% +$299K 0.29% 118
2025
Q4 		$12.5M Sell
352,387
-231,498
-40% -$6.51M 0.27% 135
2025
Q3 		$8.38M Buy
583,885
+63,758
+12% +$755K 0.19% 197
2025
Q2 		$3.73M Buy
520,127
+38,886
+8% +$216K 0.09% 340
2025
Q1 		$2.88M Buy
481,241
+24,193
+5% +$190K 0.07% 376
2024
Q4 		$3.56M Sell
457,048
-5,140
-1% -$51.2K 0.08% 393
2024
Q3 		$4.99M Buy
462,188
+2,250
+0.5% +$21.9K 0.11% 319
2024
Q2 		$3.88M Sell
459,938
-245,693
-35% -$1.86M 0.08% 380
2024
Q1 		$4.74M Buy
705,631
+385,315
+120% +$2.38M 0.1% 334
2023
Q4 		$1.88M Buy
320,316
+53,782
+20% +$412K 0.04% 505
2023
Q3 		$2.6M Sell
266,534
-523
-0.2% -$6.2K 0.06% 414
2023
Q2 		$3.16M Buy
267,057
+78,310
+41% +$898K 0.07% 386
2023
Q1 		$2.04M Buy
188,747
+69,582
+58% +$890K 0.06% 401
2022
Q4 		$1.38M Sell
119,165
-1,883
-2% -$23.3K 0.04% 449
2022
Q3 		$1.81M Buy
+121,048
New +$1.66M 0.05% 432

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kennedy Capital Management's COGT Position: Q2 2026 in Review

Kennedy Capital Management reduced its Cogent Biosciences (COGT) stake by 1.9% in Q2 2026, selling an estimated $234K and leaving 353,790 shares worth $13.7M. The position accounts for 0.24% of the portfolio, ranked #146.

Kennedy Capital Management first reported a position in COGT in Q3 2022 and has held it in 16 quarters since. The position peaked at $13.9M in Q1 2026. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Kennedy Capital Management held 353,790 shares of Cogent Biosciences worth $13.7M as of Q2 2026.
  • Kennedy Capital Management sold 6,700 Cogent Biosciences shares in Q2 2026, an estimated $234K.
  • Cogent Biosciences made up 0.24% of Kennedy Capital Management's portfolio in Q2 2026, its #146 holding.
  • Kennedy Capital Management first reported a position in Cogent Biosciences in Q3 2022 and has held it in 16 quarters since.
  • Kennedy Capital Management's Cogent Biosciences position peaked at $13.9M in Q1 2026.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.